Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes

Diabetes

Volumn 56, Issue 6, 2007, Pages 1727-1730

  Araki, Shin Ichi ^a   Haneda, Masakazu ^b   Koya, Daisuke ^c   Hidaka, Hideki ^d   Sugimoto, Toshiro ^a   Isono, Motohide ^a   Isshiki, Keiji ^a   Chin Kanasaki, Masami ^a   Uzu, Takashi ^a   Kashiwagi, Atsunori ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c Kanazawa Medical University   (Japan)

^d SANYO ELECTRIC CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; RISK REDUCTION;

AGED; ALBUMINURIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK REDUCTION BEHAVIOR; SURVIVAL ANALYSIS;

EID: 34249746896     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-1646     Document Type: Article

References (20)

1. American Diabetes Association: Nephropathy in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S79-S83, 2004
2. Gæde P, Tarnow L, Vedel P, Parving HH, Pedersen O: Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 19:2784-2788, 2004
3. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001
4. Garg JP, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 7:35-43, 2002
5. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS Group: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225-232, 2003
6. Mogensen CE: Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 254:45-66, 2003
7. Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
8. Basi S, Lewis JB: Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 47:927-946, 2006
9. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348:2285-2293, 2003
10. Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A, Koya D: Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 54:2983-2987, 2005
11. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB: Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 9:1501-1515, 1990
12. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 157:1413-1418, 1997
13. Berton G, Cordiano R, Palmieri R, De Toni R, Guarnieri GL, Palatini P: Albumin excretion in diabetic patients in the setting of acute myocardial infarction: association with 3-year mortality. Diabetologia 47:1511-1518, 2004
14. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, Cavallo-Perin P; Casale Monferrato Study: Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetologia 48:427-434, 2005
15. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45:198-202, 2005
16. Knobler H, Zornitzki T, Vered S, Oettinger M, Levy R, Caspi A, Faraggi D, Livschitz S: Reduced glomerular filtration rate in asymptomatic diabetic patients: predictor of increased risk for cardiac events independent of albuminuria. J Am Coll Cardiol 44:2142-2148, 2004
17. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1306, 2004
18. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352:2049-2060, 2005
19. Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van Lente F, Wang X, Wright JT Jr; AASK Study Group: A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. J Am Soc Nephrol 15:3175-3183, 2004
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470, 1999